August 24, 2012 — On August 20, 2012, InSightec announced it received approval from the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials evaluating the use of its ExAblate Neuro system for the treatment of patients with tremor-dominant Parkinson’s Disease (PD). This device is the first clinical system to use magnetic resonance- (MR) guided focused ultrasound (MRgFUS) through an intact skull, offering noninvasive transcranial treatment without any incisions or ionizing radiation.